中文网站正在持续更新中,请密切关注我们康肽生物的最新动态,或点击访问右上角的英文官方网站 www.phoenixpeptide.com
PHOENIX PHARMACEUTICALS, INC. TOP HOME PAGE
Top Catalog English Version | My Account | 联系我们 | China



 多肽



 标记多肽 



 多肽激素文库



 抗体 



 免疫试剂盒 



 生物标志物阵列 



 多肽样品检测



 自定义肽链合成及GMP



 产品目录索取



 样品准备



 提问和解答


Agouti-Related Protein (AGRP)(Human)

Agouti-Related Protein (AGRP), first identified by Ollman and co-workers is a potent antagonist of MC3-R and MC4-R and is an integral component in the metabolic processes that regulate feeding behavior and body weight. Present in the hypothalamus, AGRP levels are elevated in obese males (Katsuki et al, 2001). Phoenix Pharmaceuticals, Inc., in collaboration with UC San Francisco and UC Berkeley, has not only identified and synthesized several AGRP fragments that are as potent inhibitors of MC3-R and MC4-R as the parent molecule, but also the intact protein, AGRP Form C (Jimenez et al, 1999). Powerful immunological tools have been developed from these compounds that enable researchers to probe the metabolic processes that lead to obesity.

N-Terminal Domain of AGRP: Inhibiting Active form of ARGP binds to MC4R

Structural and molecular evolutionary analysis of Agouti and Agouti-related proteins.

Agouti (ASIP) and Agouti-related protein (AgRP) are endogenous antagonists of melanocortin receptors that play critical roles in the regulation of pigmentation and energy balance, respectively, and which arose from a common ancestral gene early in vertebrate evolution. The N-terminal domain of ASIP facilitates antagonism by binding to an accessory receptor, but here we show that the N-terminal domain of AgRP has the opposite effect and acts as a prodomain that negatively regulates antagonist function. Computational analysis reveals similar patterns of evolutionary constraint in the ASIP and AgRP C-terminal domains, but fundamental differences between the N-terminal domains. These studies shed light on the relationships between regulation of pigmentation and body weight, and they illustrate how evolutionary structure function analysis can reveal both unique and common mechanisms of action for paralogous gene products.

Jackson et al. Chem Biol. 2006 Dec;13(12):1297-305.

A synthetic human Agouti-related protein-(83-132)-NH2 fragment is a potent inhibitor of melanocortin receptor function.

Chemical synthesis of Agouti proteins - Agouti and Agouti-related proteins - is complicated by their large size and by multiple cysteine residues located in the carboxyl terminal regions. Three human Agouti-related protein (AGRP) fragments, two of which correspond to a proposed endoprotease cleavage site between amino acids 82 and 83, were synthesized and tested for anti-melanotropic activity using Xenopus laevis dermal melanophores. Amino-terminal fragments AGRP(25-51) and (54-82) were devoid of significant antagonist activity, whereas the amidated carboxyl-terminal AGRP fragment (83-132)-NH2 was potently active with an inhibitory equilibrium dissociation constant (Ki) of 0.7 nM. The ability to synthesize functionally active AGRP should help unravel its role in the central nervous system and its unusual properties with respect to interaction with the melanocortin family of G-protein coupled receptors.

Quillan et al. FEBS Lett 1998 May 22;428(1-2):59-62

 

A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo.

Agouti-related protein (Agrp) is present in rat and human hypothalamus and is structurally related to agouti protein. Overexpression of either of these proteins results in obesity. However the effect of exogenous Agrp and its in vivo interaction with alpha-melanocyte stimulating hormone (alphaMSH), the likely endogenous melanocortin 3 and 4 receptor (MC3-R and MC4-R) agonist, have not been demonstrated. We report that 1 nmol of Agrp(83-132), a C-terminal fragment of Agrp, when administered intracerebroventricularly (ICV) into rats, increased food intake over a 24-h period (23.0+/-1.4 g saline vs 32.9+/-2.3 g Agrp, p<0.05). The hyperphagia was similar to that seen when 1 nmol of the synthetic MC3-R and MC4-R antagonist SHU9119 was given i.c.v. (19.6+/-1.8 g saline vs 32.5+/-1.7 g SHU9119, p<0.001). Both Agrp(83-132) and SHU9119 blocked the reduction in 1-h food intake of i.c.v. alphaMSH at the beginning of the dark phase. This effect occurred independently of whether the antagonists were administered simultaneously, or nine hours prior, to the alphaMSH. We have also shown Agrp(83-132) is an antagonist at the MC3-R and MC4-R, with similar inhibition of cAMP activation to that previously reported for the full length peptide. In conclusion, Agrp(83-132) administered i.c.v. increases feeding with long lasting effects and is able to inhibit the action of alphaMSH. This interaction may be mediated by the MC3-R and/or MC4-R.

Rossi et al. Endocrinology 1998 Oct;139(10):4428-31

 

Overexpression of Agrt leads to obesity in transgenic mice.

Graham et al. Nat Genet. 1997 Nov;17(3):273-4.

 

Plasma levels of agouti-related protein are increased in obese men

To investigate the relationship between peripheral blood levels of agouti-related protein (AGRP) and various parameters of obesity, we measured the plasma level of AGRP in 15 obese and 15 nonobese men and evaluated its relationship with body mass index (BMI), body fat weight, and visceral, sc, and total fat areas measured by computed tomography, fasting insulin levels, glucose infusion rate during an euglycemic hyperinsulinemic clamp study, serum leptin, and plasma alpha-MSH. Obese men had significantly higher plasma concentrations of AGRP than nonobese men (P < 0.01). Univariate analysis showed that the plasma levels of AGRP are proportionally correlated with BMI, body fat weight, and sc fat area in obese men (BMI: r = 0.732, P < 0.01; body fat weight: r = 0.603, P < 0.02; sc fat area: r = 0.668, P < 0.01) and in all men (BMI: r = 0.839, P < 0.0001; body fat weight: r = 0.818, P < 0.0001; sc fat area: r = 0.728, P < 0.0001). In all men, the plasma levels of AGRP were significantly correlated with the visceral fat area (r = 0.478, P < 0.01), total fat area (r = 0.655, P < 0.0001), fasting insulin level (r = 0.488, P < 0.01), glucose infusion rate (r = -0.564, P < 0.01), serum level of leptin (r = 0.661, P < 0.0001), and the plasma level of alpha-MSH (r = 0.556, P < 0.01). In all subjects, multiple regression analysis showed that the plasma levels of AGRP are significantly (F = 15.522, r = 0.801, P < 0.03) correlated with the plasma levels of alpha-MSH, independently from the total fat area. However, the correlation between plasma levels of AGRP and serum levels of leptin was found to be dependent on the total fat area. In brief, these findings showed that the circulating levels of AGRP are increased in obese men and that they are correlated with various parameters of obesity. Although correlation does not prove causation, the results of this study suggest that peripheral AGRP may play a role in the pathogenesis of obesity.

Katsuki et al. J Clin Endocrinol Metab. 2001 May;86(5):1921-4.

 

Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein.

Expression of Agouti protein is normally limited to the skin where it affects pigmentation, but ubiquitous expression causes obesity. An expressed sequence tag was identified that encodes Agouti-related protein, whose RNA is normally expressed in the hypothalamus and whose levels were increased eightfold in ob/ob mice. Recombinant Agouti-related protein was a potent, selective antagonist of Mc3r and Mc4r, melanocortin receptor subtypes implicated in weight regulation. Ubiquitous expression of human AGRP complementary DNA in transgenic mice caused obesity without altering pigmentation. Thus, Agouti-related protein is a neuropeptide implicated in the normal control of body weight downstream of leptin signaling.

Ollmann et al. Science. 1997 Oct 3;278(5335):135-8.

 

Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice.

We have isolated cDNA clones that encode a novel human gene related to agouti. Sequence analysis of this gene, named ART, for agouti-related transcript, predicts a 132-amino-acid protein that is 25% identical to human agouti. The highest degree of identity is within the carboxyl terminus of both proteins. Like agouti, ART contains a putative signal sequence and a cysteine rich carboxyl terminus, but lacks the region of basic residues and polyproline residues found in the middle of the agouti protein. Both agouti and ART contain 11 cysteines, and 9 of these are conserved spatially. ART is expressed primarily in the adrenal gland, subthalamic nucleus, and hypothalamus, with a lower level of expression occurring in testis, lung, and kidney. The murine homolog of ART was also isolated and is predicted to encode a 131-amino-acid protein that shares 81% amino acid identity to humans. The mouse was found to have the same expression pattern as human when assessed by RT-PCR. Examination by in situ hybridization using mouse tissues showed localized expression in the arcuate nucleus of the hypothalamus, the median eminence, and the adrenal medulla. In addition, the hypothalamic expression of ART was elevated approximately 10-fold in ob/ob and db/db mice. ART was mapped to human chromosome 16q22 and to mouse chromosome 8D1-D2. The expression pattern and transcriptional regulation of ART, coupled with the known actions of agouti, suggests a role for ART in the regulation of melanocortin receptors within the hypothalamus and adrenal gland, and implicates this novel gene in the central control of feeding.

Shutter et al. Genes Dev. 1997 Mar 1;11(5):593-602.



ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors.

The mRNA encoding an agouti related protein (ART) of unknown biochemical function was previously reported to be up-regulated in the hypothalamus of two genetically obese mouse strains. We have expressed human ART as a secreted protein in COS-7 cells, and show that recombinant ART is functionally active in inhibiting the binding of a radiolabeled alpha-melanocyte stimulating hormone (alpha-MSH) analog to the human melanocortin-3 (MC-3) and melanocortin-4 (MC-4) receptors, while it is not a potent inhibitor of the human melanocortin-5 (MC-5) receptor. ART is an antagonist of the human MC-3 and MC-4 receptors as determined in functional assay. ART appears to be approximately 100-fold more potent than agouti with reference to the MC-3R and MC-4R binding affinity. These data suggest that ART may be a physiological regulator of feeding behavior.

Fong et al. Biochem Biophys Res Commun. 1997 Aug 28;237(3):629-31.

Immunohistochemistry demonstrates dense hypothalamic neuronal fibers expressing AGRP in the diestrous rat (G-003-53)

Figure 2. AGRP immunoreactivity is found in hypothalamic fibers projecting from the ARC as well as in the PVH (a) and DMH and PH nuclei (b). Preabsorption with the immunizing peptide AGRP-(83-132) blocks the staining reaction (c). Bars, 100 µm.

Haskell-Luevano et al. Endocrinology. 1999 Mar;140(3):1408-15.

 

Hypophysiotropic Thyrotropin-Releasing Hormone- Synthesizing Neurons in the Human Hypothalamus Are Innervated by Neuropeptide Y, Agouti-Related Protein, and a-Melanocyte-Stimulating Hormone (H-003-53)

The association between axon terminals containing NPY, AGRP,and aMSH immunoreactivity (arrows) with TRH-positive perikarya in the PVN is shown in A–F. A multipolar TRH-IR neuron is heavily contacted by NPY-IR axon terminals (A). AGRP-IR axon varicosities establish numerous axo-somatic and axo-dendritic connections with a TRH-positive cell (B). aMSH-IR axon varicosities densely cover the dendrite of a TRH-containing neuron (C). Similar associations between NPY-, AGRP-, and aMSH-IR axon terminals and TRH-containing cells are shown in 1-µm thick sections in D–F. Scale bar, 20 µm.

Mihály et al. J Clin Endocrinol Metab. 2000 Jul;85(7):2596-603.

 

Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. (H-003-57)

Sample preparation: Rats were deeply anesthetized. Their brains were perfused via the ascending aorta briefly with heparinized saline, followed by a mixture of 3.75% acrolein and 2% paraformaldehyde in 0.1 M phosphate buffer (PB) for 10~20 min. After perfusion, the brains were removed, postfixed by immersion in 2% paraformaldehyde for 1~2 h, and stored in 0.01M PBS, pH7.4, until prepared for immunohistocheistry. Thirty-micrometer-thick hypothalamic sections were stored in a cryoprotectant solution (20% glycerol and 30% ethylene glycol in 0.05 M PB) at -20°C until they were prepared for immunolabeling.

Single labeling Immunohistochemistry: Sections were treated with 1% sodium borohydride for 30 min (dissolved in distilled water for light microscopy or in 0.05M PB for electron microscopy) followed by 0.5% hydrogen peroxide in PBS for 15 min. Sections intended for light microscopy were washed in PBS for 15 min. 0.5% Triton X-100 for 1-4 h, and sections intended for electron microscopy were rinsed in PBS only. After preincubation in 10% normal horse serum for 1 h, sections were placed in a rabbit antiserum against AGRP

(Phoenix Pharmaceuticals, Inc., Belmont, CA) at 1:4,000~8,000 for light microscopy and 1:6,000 for electron microscopy. Antiserum was diluted in PBS containing 1% normal horse serum, 0.008% sodium azide, and 0.2% Kadak Photo -Flo and was incubated with the sections for 3 days, at 4°C, under continuous gentle agitation on a rotary shaker. The sections were washed in PBS three times and incubated in biotinylated antirabbit IgG (1:200, Vector Laboratories, Inc., Burlingame, CA) for 3 hours at room temperature.

After three washes in PBS, the sections were incubated in avidin -biotin -peroxidase complex (ABC Elite, 1:100, Vector Laboratories, Inc.) for 1 h and rinsed in 0.05 M Tris buffer, and immunolabeling was visualized with a mixture of 0.025% diaminobenziding (DAB) and 0.0036% hydrogen peroxide for 7~12 min. Development was terminated by extensive washing in 0.05 M Tris buffer. Sections for light microscopy were mounted onto gelatin-coated slides, air-dried, dehydrated, and coverslipped. Sections for electron microscopy, containing the PVN, were further processed for double immunolabeling.

Specificity of immunolabeling was established by preabsorption of the working dilution of the antiserum with the peptide antigen [AGRP(83-132) -NH2; Phoenix Pharmaceuticals, Inc.] at 10 µM.

Legradi et al. Endocrinology. 1999 Aug;140(8):3643-52.

Agouti-Related Protein 83-132-Amide (Human) Antibody [AGRP (83-132)(Human)-NH2] For Immunohistochemistry (H-003-53)

 
  light microscopy electron microscopy
Working Dilution 1:4000~8000 1:6000
Species Reactivity Human, Rat  

 

Cross Reactivity

 
Peptide % Crossreactivity
AGRP(83-132) (Human)-NH2 100%
Agouti-Related Protein Form C-NH2 (Human)  100%
Alpha-CGRP (Rat) 0%
Alpha-CGRP (Human) 0%
NPY (Human) 0%
Leptin (Human) 0%
Orexin-A (Human) 0%
Orexin-B (Human) 0%
MCH (Rat) 0%
Alpha-MSH 0%
 

AGRP (83-132) Amide (Human) RIA Kit (RK-003-53)

AGRP (83-132) Amide (Human) EIA Kit (EK-003-53) and Fluorescent EIA Kit (FEK-003-53)

Linear Range: 0.09-0.61ng/ml

Linear Range: 11.2 – 108 pg/ml
8 times more sensitive than normal EIA Kit

AGRP (71-132) Form C-Amide (Human) EIA Kit (EK-003-55) and Fluorescent EIA Kit (FEK-003-55)

Linear Range: 0.17-1.09ng/ml

Linear Range: 28.4-298 pg/ml
6 times more sensitive than normal EIA Kit

Quantitation of AGRP (83-132) (Human) by Dot Blot Kit (DBK-003-53)

AGRP (83-132) (Human) by Western Blot Kit (WBK-003-53) & Dot Blot Kit (DBK-003-53)

AGRP (83-132) (Mouse) by Western Blot Kit (WBK-003-57)

AGRP (83-131) (Mouse) Antibody (H-003-57)

AGRP (83-132)-Amide (Human) - FITC Labeled (FG-003-53B)

AGRP (Human) Prohormone

AGRP (Mouse)

 

Agouti-Related Protein (Mouse, Human) and Agouti Peptide Sequence Comparison

%agrp%


分类搜索
关键字搜索
按字母搜索
A B C D E F G H I J K L M N
O P Q R S T U V W X Y Z

Copyright 2019 PHOENIX BIOTECH